Come up with a name for your new list and we'll add to it:
Synchroneuron raised a round of funding on February 06, 2012. Investors include
Morningside Group (晨兴集团).
Synchroneuron is a biopharmaceutical company that develops new therapies for tardive dyskinesia (TD) and other related movement disorders. Tardive dyskinesia (TD) is a chronic, usually irreversible an…